Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

Those elements could eventually all contribute to Eisai's vision of a "highly transparent and neutral" dementia platform that will aim to relieve the anxieties of patients and their families and ...

Eisai shares fell sharply after its Alzheimer’s drug failed to secure marketing approval in the European Union. Shares were recently 12% lower at 5,852 yen, or about $38.06, Monday morning after ...

The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi, nearly three months after it recommended approval for the drug to treat some ...

Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. FDA has accepted Eisai's Biologics License Application for lecanemab-irmb, marketed as LEQEMBI, which is designed for subcutaneous ...

Eisai and Biogen update on lecanemab's EU regulatory review for early Alzheimer’s disease treatment following positive CHMP opinion. Eisai Co., Ltd. and Biogen Inc. have provided an update on ...